Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis

Company Overview

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.

Key Stats

• Today's Range: C$12.35 to C$12.49
• 50-Day Range: C$11.04 to C$14.56
• 52-Week Range: C$8.01 to C$19.69
• Volume: 8,728 shs
• Average Volume: 33,606 shs
• Market Capitalization: C$222.98 million
• P/E Ratio: 13.72
• Dividend Yield: N/A
• Price Target: C$14.75
• Consensus Rating: Moderate Buy

Cipher Pharmaceuticals Stock Analysis - MarketRank™

Cipher Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cipher Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cipher Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cipher Pharmaceuticals is 13.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cipher Pharmaceuticals is 13.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.72.

Price to Book Value per Share Ratio

Cipher Pharmaceuticals has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CPH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cipher Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Cipher Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CPH.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Cipher Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cipher Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

1 people have searched for CPH on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Cipher Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cipher Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$47,215.00 in company stock.

Percentage Held by Insiders

42.00% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.38% of the stock of Cipher Pharmaceuticals is held by institutions.

CPH Stock Analysis - Frequently Asked Questions

How have CPH shares performed this year?

Cipher Pharmaceuticals' stock was trading at C$14.32 at the beginning of 2025. Since then, CPH shares have decreased by 13.3% and is now trading at C$12.42.
View the best growth stocks for 2025 here.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc. (TSE:CPH) posted its earnings results on Thursday, August, 10th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.15 by $0.01. The company earned $7.10 million during the quarter, compared to the consensus estimate of $7.46 million. Cipher Pharmaceuticals had a net margin of 59.92% and a trailing twelve-month return on equity of 17.93%.
Read the conference call transcript.

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Cipher Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Enbridge (ENB), Bellatrix Exploration (BXE), Crescent Point Energy (CPG), Manulife Financial (MFC), Surge Energy (SGY) and Toronto-Dominion Bank (TD).

Company Calendar

• Last Earnings: 8/10/2023
• Today: 5/23/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:CPH
• Previous Symbol: TSE:DND
• CIK: N/A
• Web: www.cipherpharma.com
• Phone: +1-905-6025840
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$14.75
• High Stock Price Target: C$17.00
• Low Stock Price Target: C$12.50
• Potential Upside/Downside: +18.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C$0.91
• Trailing P/E Ratio: 13.72
• Forward P/E Ratio: 9.62
• P/E Growth: N/A
• Net Income: C$11.41 million
• Net Margins: 59.92%
• Pretax Margin: N/A
• Return on Equity: 17.93%
• Return on Assets: 7.90%

Debt

• Debt-to-Equity Ratio: 41.22
• Current Ratio: 2.00
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: C$19.03 million
• Price / Sales: 11.71
• Cash Flow: C$3.52 per share
• Price / Cash Flow: 3.53
• Book Value: C$3.96 per share
• Price / Book: 3.14

Miscellaneous

• Outstanding Shares: 17,953,309
• Free Float: N/A
• Market Cap: C$222.98 million
• Optionable: Not Optionable
• Beta: 1.20